GB2335192A - Models for neurodegenerative diseases - Google Patents
Models for neurodegenerative diseases Download PDFInfo
- Publication number
- GB2335192A GB2335192A GB9903955A GB9903955A GB2335192A GB 2335192 A GB2335192 A GB 2335192A GB 9903955 A GB9903955 A GB 9903955A GB 9903955 A GB9903955 A GB 9903955A GB 2335192 A GB2335192 A GB 2335192A
- Authority
- GB
- United Kingdom
- Prior art keywords
- peptide
- protein
- cell
- proteins
- models
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract description 14
- 230000004770 neurodegeneration Effects 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 150000007523 nucleic acids Chemical class 0.000 abstract description 18
- 108020004707 nucleic acids Proteins 0.000 abstract description 17
- 102000039446 nucleic acids Human genes 0.000 abstract description 17
- 230000002776 aggregation Effects 0.000 abstract description 16
- 238000004220 aggregation Methods 0.000 abstract description 16
- 241001465754 Metazoa Species 0.000 abstract description 11
- 239000002299 complementary DNA Substances 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 239000013598 vector Substances 0.000 abstract description 11
- 230000004048 modification Effects 0.000 abstract description 10
- 238000012986 modification Methods 0.000 abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 5
- 208000023105 Huntington disease Diseases 0.000 abstract description 4
- 108091000054 Prion Proteins 0.000 abstract description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract description 2
- 102000016252 Huntingtin Human genes 0.000 abstract description 2
- 108050004784 Huntingtin Proteins 0.000 abstract description 2
- 102100034452 Alternative prion protein Human genes 0.000 abstract 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 21
- 238000000034 method Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 7
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000035508 accumulation Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 108091005573 modified proteins Proteins 0.000 description 6
- 102000035118 modified proteins Human genes 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004931 aggregating effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 241000246020 Teline Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9802145A FR2777015B3 (fr) | 1998-02-23 | 1998-02-23 | Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB9903955D0 GB9903955D0 (en) | 1999-04-14 |
| GB2335192A true GB2335192A (en) | 1999-09-15 |
Family
ID=9523246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9903955A Withdrawn GB2335192A (en) | 1998-02-23 | 1999-02-23 | Models for neurodegenerative diseases |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPH11285382A (ja) |
| DE (1) | DE19907493A1 (ja) |
| FR (1) | FR2777015B3 (ja) |
| GB (1) | GB2335192A (ja) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6787139B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6808712B2 (en) | 1997-12-02 | 2004-10-26 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6875434B1 (en) | 1997-12-02 | 2005-04-05 | Neuralab Limited | Methods of treatment of Alzheimer's disease |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7871615B2 (en) | 2003-05-30 | 2011-01-18 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7977316B2 (en) | 1999-06-01 | 2011-07-12 | Elan Pharmaceuticals, Inc. | Prevention and treatment of amyloidogenic diseases |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8105594B2 (en) | 1998-05-21 | 2012-01-31 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
| US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8715643B2 (en) | 2008-04-09 | 2014-05-06 | Tokyo Metropolitan Institute Of Medical Science | TDP-43-storing cell model |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US9644025B2 (en) | 2007-10-17 | 2017-05-09 | Wyeth Llc | Immunotherapy regimes dependent on ApoE status |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005231998A (ja) * | 2000-02-01 | 2005-09-02 | Zeria Pharmaceut Co Ltd | 透析アミロイド線維重合核の製造方法及び透析アミロイド−シス治療剤のスクリーニング方法並びに透析アミロイドーシス治療剤 |
| CN1325652C (zh) * | 2005-10-13 | 2007-07-11 | 上海交通大学 | 提高外源蛋白在转基因植物中累积的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005466A1 (en) * | 1993-08-12 | 1995-02-23 | Institute Of Psychiatry | Models of alzheimer's disease |
-
1998
- 1998-02-23 FR FR9802145A patent/FR2777015B3/fr not_active Expired - Lifetime
-
1999
- 1999-02-17 JP JP11038522A patent/JPH11285382A/ja active Pending
- 1999-02-22 DE DE19907493A patent/DE19907493A1/de not_active Withdrawn
- 1999-02-23 GB GB9903955A patent/GB2335192A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005466A1 (en) * | 1993-08-12 | 1995-02-23 | Institute Of Psychiatry | Models of alzheimer's disease |
Non-Patent Citations (1)
| Title |
|---|
| J.Biol.Chemistry (1998) 273(11) pp.6277-6284 - Tomita et al. * |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818218B2 (en) | 1997-12-02 | 2004-11-16 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US8642044B2 (en) | 1997-12-02 | 2014-02-04 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
| US8034339B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
| US6787139B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787138B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6787144B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US8535673B2 (en) | 1997-12-02 | 2013-09-17 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
| US6787143B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6890535B1 (en) | 1997-12-02 | 2005-05-10 | Neuralab Limited | Pharmaceutical compositions and methods for treatment of amyloid diseases |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6808712B2 (en) | 1997-12-02 | 2004-10-26 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| US6936246B1 (en) | 1997-12-02 | 2005-08-30 | Neuralab Limited | Passive immunization of ASCR for prion disorders |
| US6982084B2 (en) | 1997-12-02 | 2006-01-03 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6875434B1 (en) | 1997-12-02 | 2005-04-05 | Neuralab Limited | Methods of treatment of Alzheimer's disease |
| US8034348B2 (en) | 1997-12-02 | 2011-10-11 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
| US9051363B2 (en) | 1997-12-02 | 2015-06-09 | Janssen Sciences Ireland Uc | Humanized antibodies that recognize beta amyloid peptide |
| US7893214B2 (en) | 1997-12-02 | 2011-02-22 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US8105594B2 (en) | 1998-05-21 | 2012-01-31 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US7977316B2 (en) | 1999-06-01 | 2011-07-12 | Elan Pharmaceuticals, Inc. | Prevention and treatment of amyloidogenic diseases |
| US8124081B2 (en) | 1999-06-01 | 2012-02-28 | Crimagua Limited | Prevention and treatment of amyloidogenic diseases |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US8128928B2 (en) | 2002-03-12 | 2012-03-06 | Wyeth Llc | Humanized antibodies that recognize beta amyloid peptide |
| US7871615B2 (en) | 2003-05-30 | 2011-01-18 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US8916165B2 (en) | 2004-12-15 | 2014-12-23 | Janssen Alzheimer Immunotherapy | Humanized Aβ antibodies for use in improving cognition |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US8613920B2 (en) | 2007-07-27 | 2013-12-24 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US9644025B2 (en) | 2007-10-17 | 2017-05-09 | Wyeth Llc | Immunotherapy regimes dependent on ApoE status |
| US8715643B2 (en) | 2008-04-09 | 2014-05-06 | Tokyo Metropolitan Institute Of Medical Science | TDP-43-storing cell model |
| US9128081B2 (en) | 2008-04-09 | 2015-09-08 | Tokyo Metropolitan Institute Of Medical Science | TDP-43-storing cell model |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19907493A1 (de) | 1999-08-26 |
| JPH11285382A (ja) | 1999-10-19 |
| GB9903955D0 (en) | 1999-04-14 |
| FR2777015B3 (fr) | 2000-09-15 |
| FR2777015A1 (fr) | 1999-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2335192A (en) | Models for neurodegenerative diseases | |
| Fernandez-Gamba et al. | Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease | |
| Neve et al. | Alzheimer’s disease: a dysfunction of the amyloid precursor protein | |
| Chen et al. | Posttranslational modifications of tau-Role in human tauopathies and modeling in transgenic animals | |
| Eschbach et al. | α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models | |
| Maekawa et al. | The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities | |
| Paleologou et al. | α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy | |
| Magin et al. | Emerging functions: diseases and animal models reshape our view of the cytoskeleton | |
| Daude et al. | Biological properties of the PrP-like Shadoo protein | |
| Burke et al. | The nuclear envelope in muscular dystrophy and cardiovascular diseases | |
| EP3914071A1 (en) | Human genomic construct reporter cells and mouse models to screen therapeutics against microglia-expressed disease associated genes | |
| JP2013165715A (ja) | タンパク質重合体の重合核となりうるタンパク質又はその重合体が導入された細胞及びその製造法 | |
| EP1795895A1 (en) | A tissue-based assay system for Alzheimer-specific degeneration and pathology | |
| Schledorn et al. | Alternative salt bridge formation in Aβ—a hallmark of early-onset Alzheimer's disease? | |
| US20030148356A1 (en) | Novel APP mutation associated with an unusual Alzheimer's disease pathology | |
| Yener Ilce et al. | Cellular reprogramming: A new way to understand aging mechanisms | |
| Van Adelsberg | The role of the polycystins in kidney development | |
| Luo et al. | Tau isoforms which contain the domain encoded by exon 6 and their role in neurite elongation | |
| JP6033844B2 (ja) | タウタンパク質の多重突然変異体およびヒトタウオパチーを再現するためのその使用 | |
| Tsintzas et al. | Using Drosophila amyloid toxicity models to study Alzheimer's disease | |
| Goulding et al. | The homeobox in vertebrate development | |
| Orosz et al. | TPPP/p25: A new unstructured protein hallmarking synucleinopathies | |
| JPWO2007108434A1 (ja) | 凝集体形成性タンパク質分解用の発現コンストラクト、及び凝集体形成性タンパク質が凝集体を形成することを抑制する方法 | |
| Gamliel et al. | Increased expression of presenilin 2 inhibits protein synthesis | |
| Bryan et al. | Site-specific C-terminal fluorescent labeling of Tau protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |